Fisher Wallace Laboratories
New York, New York, United States
Fisher Wallace Labs develops and markets wearable neurostimulation devices for the treatment of depression, anxiety and insomnia. The company recently completed a triple-blind, randomized, control trial for the acute treatment of major depressive disorder that is pending journal publication. Under temporary FDA-Clearance, Fisher Wallace distributed 100,000 devices via 14,000 prescribers, and is currently completing its Version 2.0 device, OAK. Over the next two years, Fisher Wallace is working to obtain permanent FDA approval and clearances, as well as CE Marks (EU/UK), for the treatment of depression, anxiety and insomnia in the US, UK and Europe.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2006
- Website
- www.fisherwallace.com/
Only accessible to MedStartr community members.
Join nowWhat do you think of Fisher Wallace Laboratories?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now